Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Nations stockpile mpox vaccine amid rising geopolitical fears
9 Jul 2025, 14:48BAVA.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Bavarian Nordic Announces Major Shareholder Notification from Invesco Ltd.17 Mar 2021
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such12 Mar 2021
Bavarian Nordic A/S - Registration of Share Capital Increase of 5,150,000 New Shares Completed12 Mar 2021
Bavarian Nordic Publishes Annual Report 202012 Mar 2021
Bavarian Nordic A/S - Articles of Association12 Mar 2021
Bavarian Nordic A/S Announces Completion of Directed Issue and Private Placement of 5,150,000 New Ordinary Shares10 Mar 2021
Bavarian Nordic Reports 2021 Financial Guidance
Search

Danish vaccine maker Bavarian Nordic will supply an undisclosed European country with its smallpox and mpox vaccine under a new contract valued at over 200 million Danish Krone, the company announced Wednesday.

Bavarian Nordic sells vaccine voucher for $160 million
20 Jun 2025, 17:26BAVA.CONASDAQ Copenhagen

Danish vaccine company Bavarian Nordic has entered an agreement to sell a Priority Review Voucher for a total of $160 million, the company said Wednesday.

  • Previous
  • 1
  • 2
  • 3
  • Next
9 Mar 2021
Bavarian Nordic A/S Seeks to Strengthen its Capital Base and Commits to Ambitious Strategy on Promising COVID-19 Vaccine Candidate9 Mar 2021
Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial8 Mar 2021
Bavarian Nordic Reports Preliminary Financial Results for 202028 Jan 2021
Bavarian Nordic A/S - Articles of Association7 Jan 2021
Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma18 Dec 2020
  • Previous
  • 1
  • More pages
  • 18
  • 19
  • 20
  • More pages
  • 78
  • Next
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
Filings
927